Healthcare Industry News: HSMN NewsFeed
News Release - October 25, 2021
Helsinki University Hospital Selects MRIdian(R) System for Installation at Comprehensive Cancer CenterCenter will be the first in Finland to offer MRIdian MR-guided radiation therapy cancer treatment
CLEVELAND, Oct. 25, 2021 -- (Healthcare Sales & Marketing Network) -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Helsinki University Hospital has purchased a MRIdianŽ System to offer patients MR-guided radiation therapy at the Comprehensive Cancer Center in the new Bridge Hospital.
The Comprehensive Cancer Center is Finland's largest and most versatile cancer treatment center. The center provides personalized treatment and features modern state-of-the-art radiation therapy technology. The Comprehensive Cancer Center is the first Nordic cancer center to have undergone accreditation through the Organisation of European Cancer Institutes (OECI) and achieved the highest possible status of a Comprehensive Cancer Center. The center's expertise is internationally recognized and its treatment results are world-class. The MRIdian system will enable the team at the Comprehensive Cancer Center to offer the latest MR-guided radiation therapy technology to patients seeking personalized cancer treatment including lung, prostate, pancreas, liver cancers, and other small tumors in abdominal and pelvic areas.
"MRIdian will bring powerful capabilities to our radiation oncology department, including the ability to deliver ablative dose with tight margins through real-time soft-tissue visualization and on-table adaptive therapy," said Professor Mikko Tenhunen. "With MRIdian, we anticipate being able to treat many tumors that we deemed were previously untreatable with radiation therapy, expanding the options available to cancer patients throughout Finland."
"We are proud to have Helsinki University Hospital join the MRIdian community," said Paul Ziegler, Chief Commercial Officer at ViewRay. "As the first to offer Finland's patients the benefits of MRIdian SMART (stereotactic MR-guided adaptive radiotherapy), they will stand at the forefront of Finnish cancer care as they treat and prove what others can't."
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination helps physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable nearby organs-at-risk and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and surrounding healthy tissues, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This provides for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.
Nearly 16,000 patients have been treated with MRIdian SMART (Stereotactic MR-guided Adaptive Radiotherapy). Currently, 46 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/
The opinions and clinical experiences discussed herein are specific to the featured physicians and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in this press release are not indicative of typical or future results.
The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration. Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdianŽ MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, anticipated future orders, ViewRay's financial guidance for the full year 2021, anticipated future operating and financial performance, treatment results, therapy adoption, innovation and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.